Undisclosed C5 inhibitor / UCB - LARVOL DELTA

[VIRTUAL] Zilucoplan, an investigational peptide inhibitor of complement component 5, blocked muscle weakness in a humanized passive transfer model of immune- mediated necrotizing myopathy (EAN 2020) - P2 | "Zilucoplan is a convenient, subcutaneously self-administered macrocyclic peptide inhibitor of complement component 5 (C5) developed by Ra Pharma, currently in Phase 2 development for IMNM and in Phase 3 development for acetylcholine receptor- positive generalized myasthenia gravis (gMG). In this study, we provide preclinical evidence of the protective role for C5 inhibition by Zilucoplan in a humanized murine model of IMNM... Our data establish a central role for C5 activation in a preclinical IMNM model, supporting the therapeutic evaluation of zilucoplan in an ongoing multicenter Phase 2 IMNM clinical trial (NCT04025632)."

CNS Disorders • Complement-mediated Rare Disorders • Myasthenia Gravis • Myositis